挑戦者

Pioneering the Future of the Gut Microbiome: Hiroto Tamura's Challenge and Lessons from the Shido Program

2024-07-28臼井杏奈・本間由美子(ライター)

An interview with Hiroto Tamura, COO of Metagen Therapeutics. He discusses his transition from Nikon to a startup, his passion for gut microbiome research, and the lessons he gained from the Shido Program.

Pioneering the Future of the Gut Microbiome: Hiroto Tamura's Challenge and Lessons from the Shido Program
シェア

Pioneering the Future of the Gut Microbiome

We sat down with Hiroto Tamura, COO (Chief Operating Officer) of Metagen Therapeutics, Inc., to hear about his career transition and his passion for gut microbiome research.

Interested in leveraging AI?

Download our service materials. Feel free to reach out for a consultation.

From a Major Corporation to a Startup

Tamura began his career at Nikon, the leading precision instrument manufacturer. However, a health issue of his own led him to recognize the importance of gut bacteria, and he made the decision to move to a startup driven by a strong desire to contribute to this field.

What Drove the Change

  • Experiencing the importance of gut bacteria firsthand through his own health problems
  • A powerful conviction to "dedicate my life to gut microbiome research"
  • An aspiration to contribute to the world through Japanese-led innovation

What Metagen Therapeutics Is Working On

Metagen Therapeutics is currently pursuing three lines of business:

1. Building a Gut Microbiome Bank

The company is constructing a bank for collecting and preserving the gut microbiomes of healthy individuals, to be used in research and treatment.

2. Fecal Microbiota Transplantation (FMT)

The company is working toward the social implementation of FMT (Fecal Microbiota Transplantation) — a treatment that transplants gut bacteria from healthy individuals into patients.

3. Microbiome Drug Discovery

The company is pursuing "microbiome drug discovery," developing new therapeutic drugs from research into gut bacteria.

Lessons from the Shido Program and the Silicon Valley Dispatch

Tamura participated in the Ministry of Economy, Trade and Industry's "Shido Program" and a Silicon Valley dispatch program.

Key Takeaways

  • Understanding the global cutting edge of microbiome research trends
  • Confirming Japan's competitive advantage in gut microbiome research
  • Building a global network

Japan's Strengths

Tamura points out that Japan holds a global competitive advantage in gut microbiome research:

  • Unique gut microbiome shaped by Japanese diet: A diet rich in fermented foods and dietary fiber forms a distinctive gut microbiome
  • Superiority in cultivation technology: Japan is at the world's top level in microbial cultivation technology

Outlook Going Forward

Tamura has set the following goals:

Goals Within 3 Years

  • Social implementation of fecal microbiota transplantation treatment
  • Achieving insurance coverage

Goals Within 5 Years

  • Broader medical applications
  • Increased public awareness

Conclusion

Hiroto Tamura has left behind his career at a major corporation and is taking on the challenge of gut microbiome research — a new and demanding field.

  • He experienced the importance of gut bacteria through his own personal experience
  • At Metagen Therapeutics, he is driving the social implementation of FMT
  • He aims for global expansion leveraging Japan's strengths

Gut microbiome research holds the potential to fundamentally transform future medicine. Tamura's challenge is one to keep a close eye on.

How well do you understand AI?

Take our free 5-minute assessment covering 7 areas from AI comprehension to security awareness.

Share this article if you found it useful

シェア

Newsletter

Get the latest AI and DX insights delivered weekly

Your email will only be used for newsletter delivery.

無料診断ツール

あなたのAIリテラシー、診断してみませんか?

5分で分かるAIリテラシー診断。活用レベルからセキュリティ意識まで、7つの観点で評価します。

Learn More About 挑戦者

Discover the features and case studies for 挑戦者.